These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35453571)

  • 1. Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions.
    David S; Tan J; Siva S; Karroum L; Savas P; Loi S
    Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
    Akanda ZZ; Neeson PJ; John T; Barnett S; Hanna GG; Miller A; Jennens R; Siva S
    Transl Lung Cancer Res; 2021 Jun; 10(6):2766-2778. PubMed ID: 34295676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?
    Xing D; Siva S; Hanna GG
    Clin Oncol (R Coll Radiol); 2019 Jul; 31(7):432-443. PubMed ID: 31005381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
    Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
    [No Abstract]   [Full Text] [Related]  

  • 5. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SABR in oligometastatic breast cancer: Current status and future directions.
    Stewart R; White M; Tan J; Siva S; Karroum L; David S
    Breast; 2021 Dec; 60():223-229. PubMed ID: 34739890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.
    Masucci GV; Wersäll P; Kiessling R; Lundqvist A; Lewensohn R
    J Transl Med; 2012 May; 10():104. PubMed ID: 22616654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients.
    Morales-Orue I; Zafra-Martin J; Garcia L; Chicas-Sett R; Castilla-Martinez J; Cabezon MA; Burgos J; Lloret M; Lara PC
    Transl Cancer Res; 2020 Jan; 9(Suppl 1):S197-S206. PubMed ID: 35117963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy.
    Ratnayake G; Reinwald S; Edwards J; Wong N; Yu D; Ward R; Smith R; Haydon A; Au PM; van Zelm MC; Senthi S
    Radiother Oncol; 2022 Aug; 173():299-305. PubMed ID: 35772575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
    Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
    Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Bernstein MB; Krishnan S; Hodge JW; Chang JY
    Nat Rev Clin Oncol; 2016 Aug; 13(8):516-24. PubMed ID: 26951040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.
    Zayed S; Louie AV; Breadner DA; Palma DA; Correa RJM
    Ther Adv Med Oncol; 2023; 15():17588359231183668. PubMed ID: 37435562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
    Dohopolski M; Iyengar P
    Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
    Park SS; Dong H; Liu X; Harrington SM; Krco CJ; Grams MP; Mansfield AS; Furutani KM; Olivier KR; Kwon ED
    Cancer Immunol Res; 2015 Jun; 3(6):610-9. PubMed ID: 25701325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?
    Walshaw RC; Honeychurch J; Illidge TM
    Br J Radiol; 2016 Oct; 89(1066):20160472. PubMed ID: 27556933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimism surrounding stereotactic body radiation therapy and immunomodulation.
    Tharmalingam H; Hoskin PJ
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S9. PubMed ID: 28917247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
    Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative body radiotherapy for lung cancer.
    Franks KN; Jain P; Snee MP
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma.
    Cheung P; Thibault I; Bjarnason GA
    Curr Opin Support Palliat Care; 2014 Sep; 8(3):258-64. PubMed ID: 25090288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.